Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Evaluation of a bilayered, micropatterned hydrogel dressing for full-thickness wound healing.

Magin CM, Neale DB, Drinker MC, Willenberg BJ, Reddy ST, La Perle KM, Schultz GS, Brennan AB.

Exp Biol Med (Maywood). 2016 May;241(9):986-95. doi: 10.1177/1535370216640943. Epub 2016 Mar 31.

2.

Micropatterned Protective Membranes Inhibit Lens Epithelial Cell Migration in Posterior Capsule Opacification Model.

Magin CM, May RM, Drinker MC, Cuevas KH, Brennan AB, Reddy ST.

Transl Vis Sci Technol. 2015 Mar 27;4(2):9. eCollection 2015 Mar.

3.

An engineered micropattern to reduce bacterial colonization, platelet adhesion and fibrin sheath formation for improved biocompatibility of central venous catheters.

May RM, Magin CM, Mann EE, Drinker MC, Fraser JC, Siedlecki CA, Brennan AB, Reddy ST.

Clin Transl Med. 2015 Feb 26;4:9. doi: 10.1186/s40169-015-0050-9. eCollection 2015.

4.

Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques.

Moody MA, Santra S, Vandergrift NA, Sutherland LL, Gurley TC, Drinker MS, Allen AA, Xia SM, Meyerhoff RR, Parks R, Lloyd KE, Easterhoff D, Alam SM, Liao HX, Ward BM, Ferrari G, Montefiori DC, Tomaras GD, Seder RA, Letvin NL, Haynes BF.

J Virol. 2014 Mar;88(6):3329-39. doi: 10.1128/JVI.03309-13. Epub 2014 Jan 3.

5.

Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome.

Song H, Pavlicek JW, Cai F, Bhattacharya T, Li H, Iyer SS, Bar KJ, Decker JM, Goonetilleke N, Liu MK, Berg A, Hora B, Drinker MS, Eudailey J, Pickeral J, Moody MA, Ferrari G, McMichael A, Perelson AS, Shaw GM, Hahn BH, Haynes BF, Gao F.

Retrovirology. 2012 Oct 30;9:89. doi: 10.1186/1742-4690-9-89.

6.

HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages.

Moody MA, Yates NL, Amos JD, Drinker MS, Eudailey JA, Gurley TC, Marshall DJ, Whitesides JF, Chen X, Foulger A, Yu JS, Zhang R, Meyerhoff RR, Parks R, Scull JC, Wang L, Vandergrift NA, Pickeral J, Pollara J, Kelsoe G, Alam SM, Ferrari G, Montefiori DC, Voss G, Liao HX, Tomaras GD, Haynes BF.

J Virol. 2012 Jul;86(14):7496-507. doi: 10.1128/JVI.00426-12. Epub 2012 May 2.

7.

H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination.

Moody MA, Zhang R, Walter EB, Woods CW, Ginsburg GS, McClain MT, Denny TN, Chen X, Munshaw S, Marshall DJ, Whitesides JF, Drinker MS, Amos JD, Gurley TC, Eudailey JA, Foulger A, DeRosa KR, Parks R, Meyerhoff RR, Yu JS, Kozink DM, Barefoot BE, Ramsburg EA, Khurana S, Golding H, Vandergrift NA, Alam SM, Tomaras GD, Kepler TB, Kelsoe G, Liao HX, Haynes BF.

PLoS One. 2011;6(10):e25797. doi: 10.1371/journal.pone.0025797. Epub 2011 Oct 19.

8.

Primary infection by a human immunodeficiency virus with atypical coreceptor tropism.

Jiang C, Parrish NF, Wilen CB, Li H, Chen Y, Pavlicek JW, Berg A, Lu X, Song H, Tilton JC, Pfaff JM, Henning EA, Decker JM, Moody MA, Drinker MS, Schutte R, Freel S, Tomaras GD, Nedellec R, Mosier DE, Haynes BF, Shaw GM, Hahn BH, Doms RW, Gao F.

J Virol. 2011 Oct;85(20):10669-81. doi: 10.1128/JVI.05249-11. Epub 2011 Aug 10.

9.

An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum.

Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, Freel S, Moody MA, Alam SM, Tomaras GD, Ochsenbauer C, Kappes JC, Shaw GM, Hoxie JA, Robinson JE, Haynes BF.

J Virol. 2011 Jul;85(14):7029-36. doi: 10.1128/JVI.00171-11. Epub 2011 May 4.

10.

Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines.

Moody MA, Liao HX, Alam SM, Scearce RM, Plonk MK, Kozink DM, Drinker MS, Zhang R, Xia SM, Sutherland LL, Tomaras GD, Giles IP, Kappes JC, Ochsenbauer-Jambor C, Edmonds TG, Soares M, Barbero G, Forthal DN, Landucci G, Chang C, King SW, Kavlie A, Denny TN, Hwang KK, Chen PP, Thorpe PE, Montefiori DC, Haynes BF.

J Exp Med. 2010 Apr 12;207(4):763-76. doi: 10.1084/jem.20091281. Epub 2010 Apr 5.

11.

Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo.

Pichla-Gollon SL, Lin SW, Hensley SE, Lasaro MO, Herkenhoff-Haut L, Drinker M, Tatsis N, Gao GP, Wilson JM, Ertl HC, Bergelson JM.

J Virol. 2009 Jun;83(11):5567-73. doi: 10.1128/JVI.00405-09. Epub 2009 Mar 11.

12.

Ligation independent cloning vectors for expression of SUMO fusions.

Weeks SD, Drinker M, Loll PJ.

Protein Expr Purif. 2007 May;53(1):40-50. Epub 2006 Dec 13.

13.

Structure-based identification of a major neutralizing site in an adenovirus hexon.

Pichla-Gollon SL, Drinker M, Zhou X, Xue F, Rux JJ, Gao GP, Wilson JM, Ertl HC, Burnett RM, Bergelson JM.

J Virol. 2007 Feb;81(4):1680-9. Epub 2006 Nov 15.

14.

SUMO fusions and SUMO-specific protease for efficient expression and purification of proteins.

Malakhov MP, Mattern MR, Malakhova OA, Drinker M, Weeks SD, Butt TR.

J Struct Funct Genomics. 2004;5(1-2):75-86.

PMID:
15263846

Supplemental Content

Loading ...
Support Center